The corollary of these findings is that PTEN loss would upregulate the GEF activity of PREX2 and, consequently, stimulate RAC1 function, potentially rendering targeting of PREX2 in the context of PTEN-deficient melanoma a rational approach. This evidence concerns the gene RAC1 and melanoma.